
CHAPTER 25: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 11**

PHARMACY BENEFITS MANAGEMENT SERVICES**TABLE OF CONTENTS**

| SUBJECT | SECTIONS |
|----------------|-----------------|
|----------------|-----------------|

| | |
|-----------------|-------------|
| OVERVIEW | 37.0 |
|-----------------|-------------|

| | |
|------------------------------------|-------------|
| GENERAL PROGRAM INFORMATION | 37.1 |
|------------------------------------|-------------|

Providers should refer to Chapter 1 – General Information and Administration of the Medicaid Services Manual for additional information.

| | |
|--|-------------|
| PHARMACY PROVIDER ENROLLMENT AND PARTICIPATION GUIDELINES | 37.2 |
|--|-------------|

Providers should refer to Chapter 1 - General Information and Administration of the Medicaid Services Manual for additional information on provider enrollment and requirements, including general standards of participation.

Provider Qualifications

Provider Rights and Responsibilities

Record Keeping Requirements

Prohibition of Reassignment of Provider Claims

Out-of-State Providers

Provider Enrollment

Medicaid Durable Medicaid Equipment/Supplies

Medicare Enrollment

Enrollment Process

Point of Sale (POS) Enrollment

Provider Record

Reporting Changes

Reporting the IRS

| | |
|---------------------------------------|-------------|
| MEDICAID RECIPIENT ELIGIBILITY | 37.3 |
|---------------------------------------|-------------|

Providers should refer to Chapter 1 - General Information and Administration of the Medicaid Services Manual for additional information on recipient eligibility.

CHAPTER 25: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 11**

PRESCRIBERS 37.4

- Qualified Prescribers
- Prescriber Numbers
- Prescribers Who Are Not Medicaid Program Providers
- Sanctioned Providers
- Accessing Prescriber Numbers

COVERED SERVICES, LIMITATIONS, AND EXCLUSIONS 37.5

- Terms and Conditions
- Tamper-Resistant Prescription Policy
- Authorized Benefits
- Non-Covered Services
- Prior Authorization and Preferred Drug List (PDL)
- Clinical Pre-Authorization
- Monthly Service Limit
 - Limit
 - Exceptions to Limit
 - Limit Override Procedures
- Drugs with Special Payment Criteria/Limitations
 - Age and Gender Restricted Drugs
 - Allergen Extracts
 - Anti-Anxiety Drugs
 - Analeptics: Armodafinil (Nuvigil®) and Modafinil (Provigil®)
 - Androgenic Agents (Testosterone and Methyltestosterone containing products)
 - Antihistamine/Decongestant Products
 - Antipsychotic Agents
 - Diagnosis Code Requirement on All Antipsychotic Medications
 - Age and Dosage Limits
 - Aripiprazole (Aristada®)
 - Attention Deficit Hyperactivity Disorder (ADHD) and Attention Deficit Disorder (ADD) Agents
 - Behavioral Health Medications for Recipients Less than 6 Years of Age
 - Clinical Pre-Authorization for ADHD Medications for Recipients Less Than 48 Months
 - Breipiprazole (Rexulti®)
 - Buprenorphine and Buprenorphine/Naloxone Agents (Bunavail, Suboxone®, and Zubsolv®)

CHAPTER 25: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 11**

| | |
|---|--|
| Diagnosis Code Requirement | |
| Quantity Limits on Buprenorphine-Naloxone Products | |
| Concurrent Opioid Analgesic and/or Benzodiazepine Therapies | |
| Buprenorphine Buccal Film (Belbuca®) | |
| Buprenorphine Implant Kit (Probuphine®) | |
| Buprenorphine Transdermal Patches (Butrans®) | |
| Carisoprodol | |
| Contraceptive Agents | |
| Drospirenone/Ethinyl Estradiol/Levomefolate Calcium (Beyaz®) | |
| Etonogestrel (Nexplanon®) | |
| Etonogestrel/Ethinyl Estradiol Vaginal Ring (Nuvaring®) | |
| Oral Contraceptive Agents | |
| Medroxyprogesterone/Acetate Injectable | |
| Norelgestromin/Ethinyl Estradiol/Transdermal Patches (Ortho-Evra®) | |
| Deferasirox (Exjade®) | |
| Recipients 2 years of age and less | |
| Recipients 2-9 years of age | |
| Recipients 10 years of age and older | |
| Diabetic Testing Supplies | |
| Fertility Agents | |
| Granulocyte Colony Stimulating Factor Agents (Granix®/Leukine®/Neulasta®/Neupogen®) | |
| Hepatitis C Virus Direct-Acting (DAA) Antiviral Agents | |
| Hydroxyprogesterone Caproate (Makena®) | |
| Isotretinoin | |
| Ivacaftor (Kalydeco®) | |
| Ketorolac | |
| Linezolid (Zyvox®) | |
| Mosquito Repellents | |
| Quantity Limits | |
| Age Restriction | |
| Naloxone | |
| Nicotine Transdermal Patches, Gum and Spray | |
| Omalizumab (Xolair®) | |
| Orlistat | |
| Palivizumab (Synagis®) | |
| Respiratory Syncytial Virus Season | |
| Age Restriction | |
| Early Refill | |
| Maximum Number of Doses Allowed | |

CHAPTER 25: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 11**

| | |
|---|--|
| Medical Reconsideration for Palivizumab (Synagis®) | |
| Palivizumab Criteria ICD-10_CM Code and Medication List | |
| Neuromuscular Disorders | |
| Congenital Abnormalities of the Airways | |
| Chronic Lung Disease | |
| Congenital Heart Diseases (CHD) | |
| Schedule II Narcotic Agents | |
| Fentanyl Buccal, Nasal, and Sublingual Agents | |
| Diagnosis Code Requirement | |
| Age Restriction | |
| Methadone | |
| Morphine ER (Avinza®) | |
| Oxycodone/Acetaminophen 7.5/325mg (Xartemis XR®) | |
| Paliperidone (Invega Trinza®) | |
| Roflumilast (Daliresp®) | |
| Short Acting Beta ₂ Agonist Inhalers | |
| Diagnosis Code Requirement | |
| Quantity Limit | |
| Therapeutic Duplication | |
| Sildenafil (Revatio®) and Tadalafil (Adcirca®) | |
| Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combination Products | |
| Sodium Oxybate (Xyrem®) | |
| Clinical Pre-authorization | |
| Therapeutic Duplication | |
| Somatropin | |
| Suvorexant (Belsomra®) | |
| Tasimelteon (Heltioz®) | |
| Tazarotene (Tazorac®) | |
| Tedizolid Phosphate (Sivextro®) | |
| Expansion of Diagnosis Code Requirement for Selected Specialty Medications | |
| Prospective Drug Utilization Policies/Limits/Edits | |
| Duration of Therapy Limits | |
| H ₂ Antagonists and Sucralfate | |
| Proton Pump Inhibitors (PPIs) | |
| Early Refill | |
| Duplicate Drug Therapy | |
| Pregnancy and FDA Category X Drugs | |
| Pregnancy and FDA Category D Drugs | |
| Therapeutic Duplication | |

CHAPTER 25: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 11**

| | |
|--|--|
| First Generation Antihistamine | |
| Second Generation Antihistamine | |
| First Generation Antihistamine-Decongestant | |
| Second Generation Antihistamine-Decongestant | |
| Angiotensin Converting Enzyme (ACE) Inhibitors and ACE Inhibitor/Diuretic Combinations | |
| ACE Inhibitors/Calcium Channel Blocker Combinations | |
| Angiotensin Receptor Antagonists (ARB) and ARB/Diuretic Combinations | |
| AR/Calcium Channel Blocker Combinations | |
| Beta-Adrenergic Blocking Agents and Beta-Adrenergic Blocking Agent/Diuretic Combinations | |
| Calcium Channel Blockers | |
| Calcium Channel Blocker/Antihyperlipemia Agent Combination | |
| Potassium Replacement | |
| Tricyclic Antidepressants | |
| Selective Serotonin Reuptake Inhibitors | |
| Antipsychotic Agents (Typical and Atypical) | |
| Antipsychotic/Selective Serotonin Reuptake Inhibitor Combinations | |
| Anti-Anxiety Agents | |
| Sedative Hypnotic Agents | |
| Attention Deficit Disorder (ADD) Agents | |
| Non-Steroidal Anti-Inflammatory Agents | |
| Short Acting Beta ₂ Agonist Inhalers | |
| Short Acting Opiate Agents | |
| Long Acting Opiate Agents | |
| Proton Pump Inhibitors | |
| Drug/Drug Interaction | |
| Unnecessary Drug Therapy | |
| Selective Cox-2 Inhibitor | |
| Maximum Dosage | |
| Atypical Antipsychotic Agents | |
| Agents Containing Acetaminophen or Aspirin | |
| Sedative Hypnotic Agents | |
| Tapentadol (Nucynta®) | |
| Agents containing Tramadol | |
| Botulinum Toxins OnabotulinumtoxinA (Botox®) and IncobotulinumtoxinA (Xeomin®) | |
| Hydrocodone Containing Agents | |
| Lidocaine Patches (Lidoderm®) | |

CHAPTER 25: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 11**

| | |
|---|--|
| Schedule II Narcotic Agents | |
| Serotonin Agents (Tryptans) | |
| Quantity Limitations | |
| Maximum Allowable Quantities | |
| Maintenance Medication Quantities | |
| Coverage and Limitations for Long Term Care Facility Recipients | |
| Quantities for Long Term Care Facility Recipients | |
| Co-payment Exemption | |
| Over-the-Counter Drugs | |
| Over-the-Counter Drugs for Preventive Care | |
| Diabetic Supplies | |
| Nebulizer Medications | |
| Medicare Skilled Nursing Facilities | |
| Emergency Kits | |
| Outpatient Drugs Covered by Medicare Part B | |
| Drug Services for Hospice Recipients | |

REIMBURSEMENT FOR PHARMACY SERVICES**37.6**

| | |
|---|--|
| Reimbursement Methodology | |
| National Drug Code (NDC) System | |
| Maximum Allowable Overhead Cost (Dispensing Fee) | |
| Provider Fee | |
| Usual and Customary Charges | |
| Drug Estimated Acquisition Cost | |
| Multiple Source Drugs | |
| Federal Upper Limit (FUL) Regulations | |
| Louisiana State Maximum Allowable Cost (LMAC) Regulations | |
| Override of FUL and MAC | |
| Co-payments for Prescription Services | |
| Co-payment Schedule | |
| Co-payment Exemptions | |
| Other Co-payment Policies | |
| Medicare Crossover Claims | |
| Third Party Liability Claims | |

MEDICARE PRESCRIPTION DRUG COVERAGE**37.7**

| | |
|----------|--|
| Medicare | |
|----------|--|

CHAPTER 25: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 11**

Medicare Part B Crossover Claims
General Medicare Part B Crossover Reimbursement Policies
Medicare Part B Outpatient Drug Coverage
 Immunosuppressive Drugs
 Oral Cancer Chemotherapy Drugs
 Antiemetic Drugs
 Nebulizer Drugs
 Diabetic Supplies
 Dispensing/Supply Fees
 Antihemophilia Drugs
Medicare Part D Outpatient Drug Coverage

THIRD PARTY LIABILITY/COORDINATION OF BENEFITS**37.8**

Third Party Liability
Coordination of Benefits
Pharmacy Providers' Roles
Coordination of Benefits Exemptions
Exemptions to Medicaid Program Restrictions
Claims for Recipients with Multiple Insurance Coverage
Override Capabilities and Codes

CLAIM SUBMISSION**37.9**

National Drug Code (NDC)
Drug Quantities and Units of Measurement
Prescriber Numbers
Diagnosis Codes
Overrides
 Federal Upper Limits/Louisiana Maximum Allowable Cost Limitations
 Prescriptions Limit
 Early Refills
 Ingredient Duplication
 Duration of Therapy
 Therapeutic Duplication
 Unnecessary Drug Therapy
 Drug/Drug Interaction
 Coordination of Benefits

CHAPTER 25: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 11**

| | |
|--|--------------|
| <ul style="list-style-type: none"> Pregnancy Co-payment Age and Gender Overrides Maximum Dosage Quantity Exceeds Program Maximum Prior Authorization (PA) Emergency Hospital Discharge Prescriptions for Atypical Antipsychotic Agents Lock-In Emergency Types of Pharmacy Claims <ul style="list-style-type: none"> Point of Sale (POS) Claim Submission (<i>Reference Point of Sale User Guide, Appendix D in this Chapter</i>) Electronic Claim Submission (BATCH) Hard Copy Claim Submission Claim Adjustments Time Limit for Submission of Medicaid Claims Billing for Spend-Down Medically Needy Recipients | |
| CLAIMS PROCESSING/PAYMENTS | 37.10 |
| <ul style="list-style-type: none"> Claims Processing <ul style="list-style-type: none"> Claim Entry Claim Adjudication Disposition of Claim Processing Time Frames Point of Sale (POS) Claims Paper Claims Remittance Advice Help Desk | |
| PUBLIC HEALTH SERVICES 340B DRUG PRICING PROGRAM | 37.11 |
| <ul style="list-style-type: none"> Reimbursement Methodology <ul style="list-style-type: none"> Covered Entity Contract Pharmacies | |
| TOTAL PARENTERAL NUTRITION (TPN) | 37.12 |
| <ul style="list-style-type: none"> Provider Enrollment Program Coverage <ul style="list-style-type: none"> TPN Medical Necessity Criteria Documentation Requirements | |

CHAPTER 25: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 11**

| | |
|--|--------------|
| Exclusionary Criteria | |
| Intradialytic Parenteral Nutrition Therapy | |
| Equipment and Supplies | |
| Prior Authorization | |
| Prior Authorization Requirements | |
| Prior Authorization Requests | |
| Emergency Request | |
| Medicare Crossover Claims | |
| Third Party Liability | |
| Reimbursement Methodology | |
| Claim Submission | |
| Medicaid Claims | |
| Medicare Crossover Claims | |
| Third Party Liability Claims | |
| Adjustments/Voids | |
| RESERVED | 37.13 |
| MEDICATION ADMINISTRATION | 37.14 |
| Louisiana Board of Pharmacy | |
| Pharmacist Provider Number | |
| Influenza Vaccine Administration by Pharmacist | |
| RESERVED | 37.15 |
| PATIENT COUNSELING, DRUG UTILIZATION REVIEW (DUR) | 37.16 |
| Patient Counseling | |
| Prospective Drug Utilization Review (UniDUR) | |
| Retrospective Drug Utilization Review | |
| Drug Utilization Review Board | |
| LOCK-IN PROGRAM | 37.17 |
| Choosing a Lock-In Provider | |
| Lock-In Emergencies | |
| Referrals | |

CHAPTER 25: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS**PAGE(S) 11**

RESERVED 37.18**MEDICAID FRAUD AND ABUSE 37.19**

Providers should refer to Chapter 1 – General Information and Administration of the Medicaid Services Manual for additional information on Program Integrity and Fraud and Abuse.

Recipient Prescription Verification Letters
Surveillance Utilization Review Subsystem (SURS)
Appeals

PROVIDER AUDITS 37.20

Audit Purpose
Audit Authority
Audit Overview and Process
Provider Responsibilities

MEDICAID DRUG REBATE PROGRAM 37.21

Rebate Programs
Federally Mandated Drug Rebate Program
State Supplemental Drug Rebate Program

LOUISIANA MEDICAID WEBSITE 37.22

Preferred Drug List
Clinical Drug Inquiries
Prescriber Numbers
Prior Approval Program
Recipient Eligibility
 Medicaid Eligibility Verification System (MEVS)
 Recipient Eligibility Verification System (REVS)
Point of Sale (POS) User Guide
Vendor Specifications Document for the POS System
Drug Appendices
Third Party Liability Carrier Code List
Provider Education and Communication

CHAPTER 25: PHARMACY BENEFITS MANAGEMENT SERVICES

SECTION: TABLE OF CONTENTS

PAGE(S) 11

| | |
|--|---------------------|
| LIST OF DRUGS PAYABLE ON DRUG FILE | APPENDIX A |
| LIST OF DRUGS WITH AVERAGE ACQUISITION RATES | APPENDIX A-1 |
| LIST OF DESI DRUGS BY NATIONAL DRUG CODE (NDC) | APPENDIX B |
| MEDICAID DRUG FEDERAL REBATE PARTICIPATION PHARMACEUTICAL COMPANIES | APPENDIX C |
| POINT OF SALE USER GUIDE | APPENDIX D |
| PRODUCTS WITH QUANTITY LIMITS | APPENDIX E-1 |
| PRODUCTS WITH MAXIMUM DAILY DOSAGES | APPENDIX E-2 |
| FORMS | APPENDIX F |
| NCPDP UNIVERSAL CLAIM FORM AND INSTRUCTIONS | APPENDIX G |
| FORM 211 – DRUG ADJUSTMENT VOID | APPENDIX H |
| PA-01 FORM - TPN PRIOR AUTHORIZATION FORM | APPENDIX I |
| CLAIMS FILING | APPENDIX J |
| RESERVED | APPENDIX K |
| TABLE OF TAMPER RESISTANT PRESCRIPTION CRITERIA AND EXAMPLES | APPENDIX L |
| GLOSSARY AND ACRONYMS | APPENDIX M |
| FREQUENT CONTACTS | APPENDIX N |